Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$69.40 USD

69.40
1,482,486

-2.93 (-4.05%)

Updated Nov 5, 2024 12:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Can Henry Schein (HSIC) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Merit Medical (MMSI) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 25.86% and 4.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Analysts Estimate McKesson (MCK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) Q2 performance will likely reflect continued strength in its dental and medical businesses.

Henry Schein (HSIC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base

by Zacks Equity Research

Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.

Henry Schein (HSIC) Global Dental Arm Rebounds Amid Cost Woes

by Zacks Equity Research

Henry Schein's (HSIC) widespread network and channel mix along with favorable long-term trends in the dental business look encouraging.

Here's Why Henry Schein (HSIC) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Henry Schein (HSIC) Inks New Deal to Acquire Condor Dental

by Zacks Equity Research

Henry Schein's (HSIC) acquisition of a Switzerland-based dental distribution company will strengthen its presence in the attractive European market.

Why Is Henry Schein (HSIC) Down 2.5% Since Last Earnings Report?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Hold on to Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) on favorable international Dental business trends and bullish guidance.

    Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term

    by Zacks Equity Research

    Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

    Henry Schein (HSIC) Q1 Earnings Top Estimates, Gross Margin Up

    by Zacks Equity Research

    Robust performances by all three operating segments drove Henry Schein's (HSIC) first-quarter 2022 revenues.

    Henry Schein (HSIC) Tops Q1 Earnings and Revenue Estimates

    by Zacks Equity Research

    Henry Schein (HSIC) delivered earnings and revenue surprises of 7.44% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    Merit Medical (MMSI) delivered earnings and revenue surprises of 12.77% and 4.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

    by Zacks Equity Research

    Robust demand in the global dental market with the steady improvement in patient traffic is likely to have contributed to Henry Schein's (HSIC) Q1 performance.

    McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

    by Zacks Equity Research

    Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

    Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity

    by Zacks Equity Research

    Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

    Henry Schein (HSIC) Stock Moves Up 20.6%: What's Driving It?

    by Zacks Equity Research

    Henry Schein's (HSIC) stock rallied on strong fourth-quarter performance and bullish 2022 EPS guidance.

    Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now

    by Zacks Equity Research

    Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.

    Here's Why You Should Retain PerkinElmer (PKI) Stock Now

    by Zacks Equity Research

    PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

    Here's Why You Should Hold on to Haemonetics (HAE) For Now

    by Zacks Equity Research

    Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.

    DexCom (DXCM) G6 CGM System Now Available to TRICARE Members

    by Zacks Equity Research

    The availability of DexCom's (DXCM) G6 CGM System to diabetic TRICARE military members is expected to enable them to make better real-time decisions about their health.